Advertisement


Related Videos

Deborah Collyar: What's In It for Patients?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Opportunities to Optimize Cancer Policies Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement



Oct
20
Today In Oncology
PARP Rechallenge Slows Ovarian Cancer Progression in Platinum-Sensitive Disease
Preclinical Study Examines Relationship Between Aging Breast Tissue and Invasive Breast Cancer
Primary Tumor Resection Followed by Systemic Treatment vs Systemic Treatment in Metastatic Colorectal Cancer 60-Day Mortality
First-Line Fulvestrant/Palbociclib vs Letrozole/Palbociclib for Endocrine-Sensitive, HR-Positive, HER2-Negative Advanced Breast Cancer
Global Analysis of National Health System Characteristics and Breast Cancer Mortality and Stage at Diagnosis
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside